AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31999405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hijamat (wet cupping therapy) plus standard lifestyle modification
Number of subjects: 120
Study 31999405 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard lifestyle modification only)
Number of subjects: 120
Study 30229691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (face-to-face nutrition, physical activity, and stress management) for 12 months
Number of subjects: 95
Study 30229691 — intervention group
Group type: COMPARATOR
Intervention: Remotely delivered intervention (general cancer prevention)
Number of subjects: 95
Study 30229691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) quartile 4
Number of subjects: 95
Study 28714336 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma oxylipins
Number of subjects: 98
Study 28714336 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fatty acids
Number of subjects: 98
Study 26506936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid interrupted‐continuous suturing technique
Number of subjects: 78
Study 26506936 — intervention group
Group type: COMPARATOR
Intervention: Continuous suturing technique
Number of subjects: 78
Study 25856266 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment vocational rehabilitation program (Spinal Cord Injury‐Vocational Integration Program)
Number of subjects: 157
Study 25856266 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 157
Study 22971205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pharmaceutical care intervention program
Number of subjects: 171
Study 22971205 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 171
Study 19534671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine intestinal alkaline phosphatase
Number of subjects: 63
Study 19534671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17707296 — intervention group
Group type: EXPERIMENTAL
Intervention: Re‐Mission video game
Number of subjects: 375
Study 17707296 — intervention group
Group type: COMPARATOR
Intervention: Regular commercial game (control)
Number of subjects: 375
Study 15125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 150 mcg/kg
Number of subjects: 63
Study 15125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 15 mcg/kg
Number of subjects: 63
Study 15125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg
Number of subjects: 63
Study 15125352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11208845 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCV (radiotherapy plus procarbazine, lomustine, and vincristine)
Number of subjects: 674
Study 11208845 — intervention group
Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 674
Study 9928562 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) and reduced-dose radiation therapy (RT)
Number of subjects: 0
Study 9928562 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) and full-dose radiation therapy (RT)
Number of subjects: 0
Study 9928562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy starting with chemotherapy (CT)
Number of subjects: 0
Study 9928562 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating radiation therapy (RT) sooner
Number of subjects: 0
Study 9928562 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment regimens delivering CT in a short time period (Adriamycin and Cytoxan in four 3-week cycles)
Number of subjects: 0
Study 7697784 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational groups
Number of subjects: 0
Study 7697784 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills teaching
Number of subjects: 0
Study 3300561 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: metoclopramide (1mg/kg i.v. every 8 h X 3)
Number of subjects: 32
Study 3300561 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: metoclopramide and droperidol (2.5 mg i.v. every 8 h X 3)
Number of subjects: 32
Study 30032828 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated therapy (B) with radiation dose up to 84 Gy
Number of subjects: 36
Study 30032828 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (A) with radiation dose of 68 Gy
Number of subjects: 36
Study 27196986 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care (nurses permitted to provide hormonal contraceptives postpartum)
Number of subjects: 337
Study 25316134 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophysical therapy (Med Select 729)
Number of subjects: 66
Study 25316134 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 66
Study 25316134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21995867 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (20 min semi‐self‐paced)
Number of subjects: 16
Study 21995867 — intervention group
Group type: COMPARATOR
Intervention: Passive control (sitting with the opportunity of reading)
Number of subjects: 16
Study 20923992 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including interactive voice response technology, home BP monitoring, and pharmacist-led BP management
Number of subjects: 146
Study 20923992 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 18931236 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (pressure support = 8 cm H2O, positive end-expiratory pressure = 6 cm H2O)
Number of subjects: 28
Study 18931236 — intervention group
Group type: COMPARATOR
Intervention: SV (spontaneous ventilation)
Number of subjects: 28
Study 16447669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group with bilateral Neiguan (P 6) needled for 3 days
Number of subjects: 49
Study 16447669 — intervention group
Group type: COMPARATOR
Intervention: Medication group given 20 mL of Shenmai Injectio intravenously for 6 days
Number of subjects: 49
Study 16447669 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy subjects
Number of subjects: 49
Study 12476043 — intervention group
Group type: EXPERIMENTAL
Intervention: Esberitox N
Number of subjects: 53
Study 12476043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10740459 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-1 device
Number of subjects: 12
Study 10740459 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 12
Study 10740459 — intervention group
Group type: COMPARATOR
Intervention: Demineralized bone matrix (DBM)
Number of subjects: 12
Study 10740459 — intervention group
Group type: COMPARATOR
Intervention: No graft (control group)
Number of subjects: 12
Study 8526449 — intervention group
Group type: EXPERIMENTAL
Intervention: polyglactine 910
Number of subjects: 235
Study 8526449 — intervention group
Group type: EXPERIMENTAL
Intervention: polydioxanone I
Number of subjects: 235
Study 8526449 — intervention group
Group type: EXPERIMENTAL
Intervention: polydioxanone II
Number of subjects: 235
Study 8526449 — intervention group
Group type: EXPERIMENTAL
Intervention: all sutures
Number of subjects: 235
Study 8248611 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1-1.5 mg/kg) administered before retrobulbar anesthesia
Number of subjects: 80
Study 8248611 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 80
Study 2935243 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection plus continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUDR)
Number of subjects: 100
Study 2935243 — intervention group
Group type: COMPARATOR
Intervention: CHAI only
Number of subjects: 100
Study 2935243 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection plus CHAI
Number of subjects: 100
Study 2935243 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAI for patients with positive portal nodes
Number of subjects: 100
Study 2935243 — intervention group
Group type: COMPARATOR
Intervention: CHAI for patients with unresectable disease
Number of subjects: 100
Study 29796967 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal physical IPV
Number of subjects: 72
Study 29796967 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant HIV serostatus
Number of subjects: 72
Study 27551936 — intervention group
Group type: EXPERIMENTAL
Intervention: New Ball (NB)
Number of subjects: 0
Study 27551936 — intervention group
Group type: COMPARATOR
Intervention: Standard Ball (SB)
Number of subjects: 0
Study 24528927 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR24 (12-week telaprevir with 24-week peginterferon alfa-2a/ribavirin)
Number of subjects: 1147
Study 24528927 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR48 (12-week telaprevir with 48-week peginterferon alfa-2a/ribavirin)
Number of subjects: 1147
Study 24528927 — intervention group
Group type: COMPARATOR
Intervention: PR48 with placebo (48-week peginterferon alfa-2a/ribavirin)
Number of subjects: 1147
Study 24528927 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1147
Study 22575076 — intervention group
Group type: EXPERIMENTAL
Intervention: Baker's yeast β-glucan (250 mg/d)
Number of subjects: 60
Study 22575076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rice flour)
Number of subjects: 60
Study 21910332 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling + Fluoxetine
Number of subjects: 42
Study 21910332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 42
Study 21910332 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling
Number of subjects: 42
Study 21910332 — intervention group
Group type: COMPARATOR
Intervention: Hamilton's depression scale
Number of subjects: 42
Study 17391911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for fear of flying, 8 sessions
Number of subjects: 115
Study 17391911 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 115
Study 17238470 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology assisted pharmacist intervention
Number of subjects: 0
Study 17238470 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard practice)
Number of subjects: 0
Study 12679475 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (n=8)
Number of subjects: 16
Study 12679475 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=8)
Number of subjects: 16
Study 11129745 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE intervention
Number of subjects: 1531
Study 11129745 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1531
Study 8919832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg/kg administered 10 min before induction
Number of subjects: 30
Study 8919832 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 0.4 mg/kg administered 5 min after decollement of nasal septum
Number of subjects: 30
Study 2262623 — intervention group
Group type: EXPERIMENTAL
Intervention: microlipoinjection
Number of subjects: 18
Study 2262623 — intervention group
Group type: EXPERIMENTAL
Intervention: injectable collagen
Number of subjects: 18
Study 6117988 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bunitrolol (Stresson)
Number of subjects: 20
Study 6117988 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bunitrolol (Stresson)
Number of subjects: 20
Study 31642408 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological music therapy intervention for 3 months (AB group)
Number of subjects: 40
Study 31642408 — intervention group
Group type: COMPARATOR
Intervention: Neurological music therapy intervention for 3 months (BA group)
Number of subjects: 40
Study 31642408 — intervention group
Group type: COMPARATOR
Intervention: Both groups (AB and BA) during intervention period
Number of subjects: 40
Study 31396693 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) subcutaneous administration
Number of subjects: 449
Study 28276192 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of medroxyprogesterone acetate (MPA) per day
Number of subjects: 300
Study 28276192 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of medroxyprogesterone acetate (MPA) per day
Number of subjects: 300
Study 25595151 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 40,000 IU fortnightly
Number of subjects: 208
Study 25595151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 24777678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 5
Study 20957399 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 80 mg daily i.v.
Number of subjects: 3
Study 20957399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg daily i.v.
Number of subjects: 3
Study 20957399 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg daily i.m.
Number of subjects: 3
Study 18795893 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidants (vitamins C and E, and alpha‐lipoic acid)
Number of subjects: 6
Study 18795893 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee‐extensor exercise training
Number of subjects: 6
Study 18795893 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant administration after exercise training
Number of subjects: 6
Study 16970165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg once a day for 8 weeks
Number of subjects: 192
Study 16970165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 15137556 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based exercise programme (daily physical exercises supported by music for 30 min/session for three months)
Number of subjects: 25
Study 15137556 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily conversation for the same duration)
Number of subjects: 25
Study 10806470 — intervention group
Group type: EXPERIMENTAL
Intervention: Music assisted progressive muscle relaxation (M + PMR)
Number of subjects: 60
Study 10806470 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 60
Study 10806470 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 60
Study 10806470 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence/suggestion
Number of subjects: 60
Study 9314469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (125 mg perorally four times daily for 7 days)
Number of subjects: 20
Study 9314469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 20
Study 8174198 — intervention group
Group type: EXPERIMENTAL
Intervention: BH‐AC.DMP (daunorubicin, 6‐mercaptopurine, and prednisolone)
Number of subjects: 433
Study 8174198 — intervention group
Group type: COMPARATOR
Intervention: BH‐AC.AMP (aclarubicin, 6‐mercaptopurine, and prednisolone)
Number of subjects: 433
Study 8174198 — intervention group
Group type: EXPERIMENTAL
Intervention: BH‐AC.DMP (for subtype M3)
Number of subjects: 433
Study 8174198 — intervention group
Group type: COMPARATOR
Intervention: BH‐AC.AMP (for subtype M3)
Number of subjects: 433
Study 8174198 — intervention group
Group type: EXPERIMENTAL
Intervention: BH‐AC.DMP (for subtypes M1, M2, M4, and M5)
Number of subjects: 433
Study 8174198 — intervention group
Group type: COMPARATOR
Intervention: BH‐AC.AMP (for subtypes M1, M2, M4, and M5)
Number of subjects: 433
Study 3295321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX)
Number of subjects: 245
Study 3295321 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 245
Study 31461222 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection after positive sentinel node biopsy
Number of subjects: 126
Study 31461222 — intervention group
Group type: COMPARATOR
Intervention: No axillary dissection
Number of subjects: 126
Study 31874283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg
Number of subjects: 2926
Study 31874283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg
Number of subjects: 2926
Study 29294360 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once-daily
Number of subjects: 16
Study 29294360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg once-daily
Number of subjects: 16
Study 29294360 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium 44 μg once-daily
Number of subjects: 16
Study 28872637 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of intensive CBT
Number of subjects: 43
Study 28872637 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks waitlist followed by 4 weeks of CBT
Number of subjects: 43
Study 28872637 — intervention group
Group type: COMPARATOR
Intervention: 24 healthy controls before and after 4 weeks of no treatment
Number of subjects: 43
Study 26614277 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I
Number of subjects: 150
Study 26614277 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I-D
Number of subjects: 150
Study 26614277 — intervention group
Group type: COMPARATOR
Intervention: PCG
Number of subjects: 150
Study 22902063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 102
Study 22902063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 21962422 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Fitness intervention
Number of subjects: 40
Study 21962422 — intervention group
Group type: COMPARATOR
Intervention: Health education active control intervention
Number of subjects: 40
Study 18382875 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene tape (TVT‐O) placed underneath the bladder base during anterior colporrhaphy
Number of subjects: 50
Study 18382875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no polypropylene tape)
Number of subjects: 50
Study 18382875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 50
Study 17416954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% proparacaine
Number of subjects: 0
Study 17416954 — intervention group
Group type: COMPARATOR
Intervention: Subtenon 2% lidocaine
Number of subjects: 0
Study 12749495 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 12749495 — intervention group
Group type: COMPARATOR
Intervention: Control (compounds without ITNs)
Number of subjects: 0
Study 11099451 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-brain patients
Number of subjects: 4
Study 11099451 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-brain patients (pre- and post-callosotomy)
Number of subjects: 4
Study 11099451 — intervention group
Group type: COMPARATOR
Intervention: Normal and epileptic controls
Number of subjects: 4
Study 8624657 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser treatment with 10-mm spot size and 3.0 J/cm2 fluence
Number of subjects: 39
Study 8624657 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser treatment (all protocols)
Number of subjects: 39
Study 8624657 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser treatment
Number of subjects: 39
Study 1729110 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (FIO2 of 0.30)
Number of subjects: 22
Study 2857364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin D and calcium (combined index)
Number of subjects: 1954
Study 31397870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% of energy from IP-TFA
Number of subjects: 0
Study 29790480 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer Resolute Integrity zotarolimus-eluting stents (ZES)
Number of subjects: 3514
Study 29790480 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer SYNERGY everolimus-eluting stents (EES)
Number of subjects: 3514
Study 29790480 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer Orsiro sirolimus-eluting stents (SES)
Number of subjects: 3514
Study 29790480 — intervention group
Group type: COMPARATOR
Intervention: Orsiro sirolimus-eluting stents (SES)
Number of subjects: 3514
Study 27237768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 1088
Study 27237768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1088
Study 25407695 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperAmma intervention promoting handwashing with soap (HWWS) in intervention villages.
Number of subjects: 345
Study 25407695 — intervention group
Group type: COMPARATOR
Intervention: Control villages (no specific intervention mentioned).
Number of subjects: 345
Study 25407695 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperAmma intervention (reduced from 4 to 2 contact days).
Number of subjects: 345
Study 23153036 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 20% essential oil of black pepper in aloe vera gel
Number of subjects: 120
Study 23153036 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care (hot packs with or without vigorous tactile stimulation)
Number of subjects: 120
Study 19238088 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 225-375 mg/day
Number of subjects: 289
Study 19238088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 19238088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60-80 mg/day
Number of subjects: 289
Study 17989532 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy
Number of subjects: 0
Study 17989532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16107993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tenofovir disoproxil fumarate and full-dose didanosine
Number of subjects: 0
Study 16107993 — intervention group
Group type: COMPARATOR
Intervention: 1 or neither of the agents (Control)
Number of subjects: 0
Study 12553483 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine, stavudine, and nevirapine
Number of subjects: 89
Study 9794736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 2252
Study 9794736 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with demographic data and blood pressure
Number of subjects: 2252